Next-generation AI firms raise billions for programmable therapeutic design (nature.com)

• AI biology firms raise billions for drug design.
• Focus on programmable therapeutics and optimized drug design.
• Data and development bottlenecks remain key challenges.

"AI companies in biology are attracting billions in investment to accelerate drug discovery and design programmable therapeutics, but data and development bottlenecks remain."